Skip to main content

DESCIFRANDO LAS BASES MOLECULARES DE LAS ENFERMEDADES RELACIONADAS CON DESREGULACION DEL COMPLEMENTO Y APRENDIENDO COMO TRATARLAS.

SAF2015-66287-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2015
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Dirección General de Investigación Científica y Técnica
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Familial risk of developing atypical hemolytic-uremic syndrome, Familial risk of developing aHUS

  • Arjona, Emilia
  • Huerta, Ana
  • Goicoechea de Jorge, Elena
  • Rodríguez de Córdoba, Santiago
13 p.-1 fig.-1 tab.+10 p.-3 tab. (mat. supl.), .Atypical hemolytic-uremic syndrome (aHUS) is a life-threatening disease that in most cases progresses to end-stage kidney disease.1 Rare pathogenic mutations in complement components or regulatory proteins play a crucial role in the pathogenesis of aHUS in 50% to 60% of patients.2-4 These rare variants cause defective regulation of the complement alternative pathway in the endothelial cell surface, which triggers episodes of thrombotic microangiopathy in the renal microvasculature and other vital organs.5-11 Finding complement pathogenic mutations in genetic analyses, or not finding them, improves diagnosis and facilitates a personalized treatment with eculizumab, a humanized monoclonal antibody that avoids the pathological consequences of cell surface complement dysregulation.1 Genetic analyses are widely used to help clinically diagnose aHUS, and they can help identify numerous asymptomatic relatives who carry different loads of aHUS genetic risk factors. A recurring..., This work was developed under the supervision of the Spanish Registry of atypical Hemolytic Uremic Syndrome and C3-Glomerulopathy (aHUS/C3G) and was supported by the Spanish Ministerio de Economía y Competitividad/FEDER grant SAF2015-66287-R and Autonomous Region of Madrid grant S2017/BMD-3673., Peer reviewed